Inhaled hope for PAH patients: new drug aims to ease the struggle to breathe
NCT ID NCT04266197
Summary
This study tested a single inhaled dose of an experimental drug called RT234 in people with pulmonary arterial hypertension (PAH). The main goal was to see if the drug could safely improve how well participants could exercise and reduce their feeling of breathlessness during physical activity. Researchers measured this using special exercise tests and walking assessments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascension Seton Medical Center Austin
Austin, Texas, 78705, United States
-
Augusta University
Augusta, Georgia, 30912, United States
-
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, 53215, United States
-
Baylor Scott and White Institute
Dallas, Texas, 75246, United States
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Mayo Clinic
Rochester, Minnesota, 20010, United States
-
MedStar Heart and Vascular Institute
Washington D.C., District of Columbia, 20010, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
Norton Health
Louisville, Kentucky, 40202, United States
-
Ochsner Louisiana State University Health
Shreveport, Louisiana, 71103, United States
-
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California, 90502, United States
-
The Ohio State University
Columbus, Ohio, 43210, United States
-
The University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
-
Tufts University
Boston, Massachusetts, 02111, United States
-
UC Davis
Sacramento, California, 95618, United States
-
UCLA
Los Angeles, California, 90024, United States
-
University Hospital
Cleveland, Ohio, 44106, United States
-
University of Alabama
Birmingham, Alabama, 35294, United States
-
University of Arizona
Tucson, Arizona, 85724, United States
-
University of California San Francisco
San Francisco, California, 94143, United States
-
University of New Mexico
Albuquerque, New Mexico, 87131, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
University of Southern California
Los Angeles, California, 90033, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23284, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.